Vistusertib: 13 Clinical Trials, Page 1 of 2

1 2

Hide Studies Not Open or Pending


Navitoclax and Vistusertib in Treating Patients With Relapsed Small Cell Lung Cancer and Other Solid Tumors

Condition(s):Metastatic Malignant Solid Neoplasm; Recurrent Lung Small Cell Carcinoma; Recurrent Malignant Solid Neoplasm; Refractory Malignant Solid Neoplasm; Stage III Lung Small Cell Carcinoma AJCC v7; Stage IIIA Lung Small Cell Carcinoma AJCC v7; Stage IIIB Lung Small Cell Carcinoma AJCC v7; Stage IV Lung Small Cell Carcinoma AJCC v7; Unresectable Solid NeoplasmLast Updated:April 22, 2021Recruiting


mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian

Condition(s):BRCA1 Mutation Carrier; BRCA2 Mutation Carrier; Endometrial Adenocarcinoma; Estrogen Receptor Negative; HER2/Neu Negative; High Grade Ovarian Serous Adenocarcinoma; Progesterone Receptor Negative; Recurrent Breast Carcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Recurrent Uterine Corpus Carcinoma; Stage III Uterine Corpus Cancer AJCC v7; Stage IV Breast Cancer AJCC v6 and v7; Stage IV Uterine Corpus Cancer AJCC v7; Triple-Negative Breast CarcinomaLast Updated:July 21, 2020Active, not recruiting

1 2

At, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.